Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Adjuvant Rezvilutamide in Combination With Androgen Deprivation Therapy in Androgen Receptor-positive, High-risk Salivary Duct Carcinoma: a Single-arm Phase 2 Trial

NCT06348264 is registered in ClinicalTrials.gov with Peking University First Hospital as lead sponsor.

NCT NCT06348264
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06348264 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Adjuvant Rezvilutamide in Combination With Androgen Deprivation Therapy in Androgen Receptor-positive, High-risk Salivary Duct Carcinoma: a Single-arm Phase 2 Trial
Lead sponsor
Peking University First Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
October 10, 2024
Completion date
March 30, 2031
Enrollment
37 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

salivary gland neoplasm duct